The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...

Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth ...

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...

In re: Xencor, Inc., Appeal No. 2024-1870 (Fed. Cir. Mar. 13, 2025) ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming ...

Thane Wettig; Interim Chief Executive Officer, Chief Commercial Officer; FibroGen Inc. David Delucia; Vice Presi ...